BACKGROUND: Self-reports of medication adherence are subject to recall errors and social desirability bias. The visual analogue scale (VAS) is a brief measure and minimally burdensome. Its accuracy among substance users needs confirmation. METHODS: We administered the VAS on an audio computer-assisted self-interview (ACASI) to 102 HIV-positive active substance users. Viral load (VL) was obtained via chart review. Cohen κ assessed the overall agreement between VL suppression and adherence, and a receiver-operator characteristic (ROC) curve assessed the diagnostic performance. RESULTS: The VAS estimates of adherence correlated with VL. Various cutoffs for adherence were associated with VL suppression, demonstrating fair to moderate agreement through κ. Area under the curve (AUC) demonstrated that the ACASI-administered VAS strongly predicted VL suppression (AUC = 0.79). DISCUSSION: The VAS administered by ACASI is viable for measuring highly active antiretroviral therapy (HAART) adherence among substance users. Its benefits as a screening instrument may make it useful for both clinical and research purposes.
BACKGROUND: Self-reports of medication adherence are subject to recall errors and social desirability bias. The visual analogue scale (VAS) is a brief measure and minimally burdensome. Its accuracy among substance users needs confirmation. METHODS: We administered the VAS on an audio computer-assisted self-interview (ACASI) to 102 HIV-positive active substance users. Viral load (VL) was obtained via chart review. Cohen κ assessed the overall agreement between VL suppression and adherence, and a receiver-operator characteristic (ROC) curve assessed the diagnostic performance. RESULTS: The VAS estimates of adherence correlated with VL. Various cutoffs for adherence were associated with VL suppression, demonstrating fair to moderate agreement through κ. Area under the curve (AUC) demonstrated that the ACASI-administered VAS strongly predicted VL suppression (AUC = 0.79). DISCUSSION: The VAS administered by ACASI is viable for measuring highly active antiretroviral therapy (HAART) adherence among substance users. Its benefits as a screening instrument may make it useful for both clinical and research purposes.
Entities:
Keywords:
adherence; antiretroviral therapy; computerized assessment; substance use
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: S J Gange; Y Barrón; R M Greenblatt; K Anastos; H Minkoff; M Young; A Kovacs; M Cohen; W A Meyer; A Muñoz Journal: J Epidemiol Community Health Date: 2002-02 Impact factor: 3.710
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: D S Metzger; B Koblin; C Turner; H Navaline; F Valenti; S Holte; M Gross; A Sheon; H Miller; P Cooley; G R Seage Journal: Am J Epidemiol Date: 2000-07-15 Impact factor: 4.897
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Jessica H Oyugi; Jayne Byakika-Tusiime; Edwin D Charlebois; Cissy Kityo; Roy Mugerwa; Peter Mugyenyi; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2004-08-15 Impact factor: 3.731
Authors: Aimee N C Campbell; Don Des Jarlais; Cooper Hannah; Sarah Braunstein; Susan Tross; Laura Kersanske; Christine Borges; Martina Pavlicova; Kevin Jefferson; Howard Newville; Laurel Weaver; Margaret Wolff Journal: BMC Health Serv Res Date: 2016-08-02 Impact factor: 2.655